... A simple question that has remained unanswered since the discovery of the EML4-ALK fusion in 2007 is “what happens to the 5′ ALK DNA chromosomal fragment that contains ALK exons 1-19?” Routine clinical use of NGS in NSCLC allows the detection of the presence of reciprocal or nonreciprocal translocations in a subset of cases, which could not be identified using FISH or IHC platforms... Patients with ALK+ NSCLC with brain metastases but did not retain the 5′ ALK fragment had similar poor outcomes when treated with crizotinib.21 Last, whether the shorter PFS from crizotinib treatment can be translated to next-generation ALK tyrosine kinase inhibitors is also unknown. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2020.04.031
Authors: Susan J. Hsiao, Sai-Hong Ignatius Ou
